University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
15 mars 2024 07h05 HE
|
Arch Biopartners
TORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of...
[Latest] Global Hemophilia B Gene Therapy Market Size/Share Worth USD 5,938.5 Billion by 2032 at a 34.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 sept. 2023 16h00 HE
|
Custom Market Insights
Austin, TX, USA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hemophilia B Gene Therapy Market Size, Trends and Insights By Treatment Type...
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
25 mai 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System
03 nov. 2022 13h00 HE
|
GastroIntestinal Research Foundation
CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the...
COMBINEDBrain Received the Global Genes 2022 Health Equity RARE Patient Impact Grant
29 sept. 2022 11h27 HE
|
COMBINEDBrain Inc
NASHVILLE, Tenn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- COMBINEDBrain (Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders), a non-profit organization of patient advocacy...
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
28 mars 2022 09h00 HE
|
Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast Featuring Matt Stang, CEO of Delic Holdings Corp.
16 nov. 2021 08h17 HE
|
InvestorBrandNetwork (IBN)
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
10 nov. 2021 07h30 HE
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
16 sept. 2021 07h30 HE
|
Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
08 juin 2021 07h00 HE
|
Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...